Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples